foxo4-dri senolytic 2023 2024 study Computational design of peptide targeting FOXO4. a, Domains of FOXO4 Senolytic therapeutics: An emerging treatment

The drug carries risks of dependency because of its amphetamine-like mechanism

Ligament and Tendon Injuries Common in athletes and active adults, these injuries may heal more efficiently with support from BPC-157s regenerative signaling pathways

Use aseptic handling and appropriate PPE

Critical Considerations: This schedule is purely theoretical and not based on clinical evidence Individual tolerance varies dramaticallysome may not tolerate even these conservative doses Maximum combined doses would likely need to remain below monotherapy maximums (perhaps 2.4 mg cagrilintide + 8 mg retatrutide as absolute ceiling) Medical supervision would be essential throughout any such protocol Alternative Approach: Sequential Rather Than Concurrent An arguably safer alternative to simultaneous cagrilintide dosage with retatrutide administration involves sequential optimization: Optimize one compound first Reach stable, effective dose of either cagrilintide or retatrutide Assess response Evaluate metabolic effects over 12-16 weeks Introduce second compound Only if additional effects are needed Ultra-gradual second titration Even slower escalation of the added compound Continuous reassessment Regular evaluation of whether combination provides benefits beyond monotherapy This approach provides clearer attribution of effects and side effects to specific compounds, though it significantly extends the overall timeline

McBride JA, Coward RM